Heidelberg Center for Personalized Oncology

Heidelberg Center for Personalized Oncology (DKFZ-HIPO)

The rise of next generation sequencing (NGS) has opened up new opportunities for translating high-throughput genomics into clinical practice. In 2011, the DKFZ has established the Heidelberg Center for Personalized Oncology (DKFZ-HIPO), which offers a program for personalized oncology with the aim to translate latest research and technologies from the “OMICs” fields (genomics, transcriptomics, etc.) and systems biology/medicine into clinical practice.

DKFZ-HIPO integrates high-level expertise in functional genomics, systems biology and translational oncology under a unified organizational structure: HIPOgen(Genome Analysis), HIPOsys (Systems Biology), andHIPOmed (Precision Oncology) and is headed by the three HIPO directors Peter Lichter, Roland Eils, and Christof von Kalle.

The following Technology Platforms partner up in the HIPO workflow to pursue the centers’ ambitious goals: the Sample Processing Laboratory (SPL), the CHromatin And RNA Methods (CHARM) Laboratory, the High-Throughput Sequencing Unit and Microarray Unit of the DKFZ Genomics and Proteomics Core Facility (GPCF), the Data Management Group (DMG), and the HIPO Bioinformatics Platform.

During the first HIPO funding period from 2011 to 2016 the center developed the infrastructure and workflows that have allowed sample processing, DNA/RNA sequencing, data management and bioinformatics analyses in more than 60 HIPO funded projects from researchers of the DKFZ in collaboration with clinical partners. The covered entities included colorectal cancer, brain tumors, sarcoma, leukemia and lymphomas, pancreatic carcinomas, breast cancer, ovarian cancer, lung cancer, and others. Numerous publications have been published in high-ranking journals.

The second funding period, HIPO2, started end of 2016 and supports 13 larger projects dedicated to the implementation of personalized therapy approaches and the assessment of therapy response and resistance. The clinical consequences of the molecular results are discussed in Molecular Tumor Boards for novel treatment strategies. Many of the current HIPO2 projects run in a similar manner as the prospective program INFORM and the MASTER program of the Precision Oncology Program of the National Center for Tumor Diseases (NCT-POP).

Currently, HIPO also explores the integration of novel approaches with potentially high relevance in personalized oncology such as liquid biopsies and immunoprofiling.

As of today DKFZ-HIPO is a very successful and unique program that takes a pioneering role in the field of personalized oncology both national and international.

Please see the DKFZ-HIPO Homepage for further information.

© dkfz.de


HIPO Directors:

Prof. Dr. Peter Lichter
Im Neuenheimer Feld 280
69120 Heidelberg
Phone: +49 6221 42-4619
E-Mail: peter.lichter@dkfz-heidelberg.de

Prof. Dr. Roland Eils
Im Neuenheimer Feld 280
69120 Heidelberg
Phone: +49 6221 42-3601
E-Mail: r.eils@dkfz-heidelberg.de

Prof. Dr. Christof von Kalle
Im Neuenheimer Feld 460
69120 Heidelberg
Phone: +49 6221 56-6991
E-Mail: christof.kalle@nct-heidelberg.de


Dr. Katja Beck and Dr. Karolin Willmund
HIPO Coordinators
Im Neuenheimer Feld 280
69120 Heidelberg
Phone: +49 6221 42-4579/ -4577
Fax: +49 6221 42-4639

Homepage: http://www.hipo-heidelberg.org
E-Mail: hipo@dkfz-heidelberg.de

© dkfz.de

to top